Acinic Cell Carcinoma of the Breast: A Comprehensive Review

Running title: Mammary acinic cell carcinoma

Azra Ajkunic¹, Faruk Skenderi², Nada Shaker³, Saghir Akhtar⁴, Janez Lamovec⁵, Zoran Gatalica⁶, Semir Vranic⁴*

¹ Fred Hutchinson Cancer Research Center, Seattle, WA, USA
² Sarajevo School of Science and Technology, Sarajevo, Bosnia and Herzegovina
³ Department of Pathology, the Ohio State University Wexner Medical Center, Columbus, OH, USA
⁴ College of Medicine, QU Health, Qatar University, Doha, Qatar
⁵ Institute of Oncology Ljubljana, Ljubljana, Slovenia
⁶ Department of Pathology, University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA

*Correspondence
Semir Vranic, MD, PhD; College of Medicine, QU Health, Qatar University, PO Box 2713, Doha, Qatar. E-mail: semir.vranic@gmail.com or svranic@qu.edu.qa
Abstract

Acinic cell carcinoma of the breast is a rare special subtype of breast cancer in the category of salivary gland-type tumors. It is morphologically similar to acinic cell carcinomas of salivary glands and pancreas and has a triple-negative phenotype (estrogen receptor-negative, progesterone receptor-negative, and Her-2/neu negative). Its molecular genomic features are more similar to triple-negative breast cancer of no special type than to its salivary gland counterpart. However, the clinical course of the mammary acinic cell carcinoma appears to be less aggressive than the usual triple-negative breast carcinomas. This review comprehensively summarizes the current literature on the clinicopathologic, immunohistochemical, and molecular features of this rare and distinct subtype of breast cancer.

Keywords: Breast cancer – special types – salivary gland-type tumors – acinic cell carcinoma
Introduction

Breast cancer is the most common malignancy in women worldwide and the second deadliest after lung and bronchus primary [1]. Nevertheless, it is a heterogeneous and complex disease at the morphologic, molecular genetic, and clinical levels [2].

Invasive ductal carcinoma no special type (NST) is the most common subtype of breast cancer and accounts for > 70% of all breast cancers [3]. The remaining 30% comprises so-called special types of breast cancer, represented in > 15 morphologic and molecular subtypes.

A rare subgroup of the special type of breast cancer is salivary gland-like carcinomas. This review comprehensively summarizes the current knowledge on the specific variant of salivary gland-like carcinoma of the breast, known as acinic cell carcinoma (AcCC). Our literature search included PubMed/MEDLINE, Scopus, and Web of Science (Science Citation Index/Science Citation Index Expanded). The most recent literature search was performed in May 2022 (see flowchart in Figure 1).

Salivary gland-type tumors of the breast

Both salivary glands and breasts are composed of tubuloacinar glands with similar histologic structures. Acinar cells, which constitute the major component of salivary glands, have been found in breast lobules, and various types of neoplasms may occur indiscriminately in both tissues. Tumors that develop in the mammary and salivary glands share morphologic and immunohistochemical features. However, their incidence and clinical behavior differ substantially [3]. The defining genomic abnormalities in certain types of primary salivary glands’ tumors may also be detectable in the salivary gland-type primary tumors of the breast (e.g., adenoid cystic carcinoma with t(6;9), leading to the MYB-NFIB fusion, secretory carcinoma with t(12;15) and the ETV6-NTRK3 fusion, or pleomorphic adenoma with HMGA2 or PLAG1 rearrangements)
Salivary gland tumors of the breast encompass a rare and diverse group of neoplasms, including adenoid cystic carcinoma, secretory carcinoma, mucoepidermoid carcinoma, polymorphous adenocarcinoma, and acinic cell carcinoma [3, 5]. A distinct group of salivary gland tumors of the breast includes epithelial-myoepithelial tumors, some of which are benign (pleomorphic adenoma and adenomyoepithelioma), while adenoid cystic carcinoma and malignant adenomyoepithelioma are malignant [3].

AcCC is a rare malignant tumor, morphologically and ultrastructurally comparable to acinic cell carcinoma of the parotid gland. Roncaroli et al. were the first to describe this form of breast cancer in 1996 [6]. Although most breast cancers are ductal and show neither acinar nor secretory differentiation, invasive ductal carcinomas may rarely show lysosome-positive cells with granular cytoplasm. Secretory carcinoma is typically attributed to breast cancers associated with a pathognomonic ETV6-NTRK3 gene fusion. However, a broader subclass of breast carcinomas includes AcCC and cystic hypersecretory carcinomas that mimic the prosecretory phenotype of a lactating breast [7].
Epidemiology and clinical features of mammary AcCC

The actual incidence of AcCC is unknown; as of 2018/2019, approximately 50 cases have been published in the literature [3]. The largest study based on a database search included 11 patients from China [8]. A study by Zhang and colleagues (2020) identified 582 cases of triple-negative breast carcinoma (TNBC), with only one case described as AcCC (frequency of 0.2%) [9]. Our comprehensive literature search identified 68 cases published in the English-language literature between 1996 and 2022 (summarized in Table 1). We comprehensively searched PubMed/MEDLINE, Scopus, and Web of Science Core Collection (Science Citation Index Expanded/SCIE/) using the following keywords: "acinic cell carcinoma", "breast", "breast carcinoma with acinic cell differentiation", "breast carcinoma and microglandular adenosis". Conference proceedings (e.g., European Congress of Pathology, published in Virchow Archives, and Annual Meeting of the United States and Canadian Academy of Pathology/USCAP/, published in Modern Pathology/Laboratory Investigation) were excluded. These references did not include full abstracts in SCIE (Figure 1). Non-English language references were also excluded (Figure 1).

AcCC of the breast affected women between 20 and 80 years (mean 48.5 years, median: 47 years). Only a single male case has been reported [10]. As with other breast cancer subtypes, there was no predilection for any particular site in AcCC. The clinical and radiologic appearances are similar to that of other breast cancer subtypes, e.g., as a palpable, poorly definable lump/mass with microcalcifications; occasionally, other clinical and radiologic appearances may occur (e.g., lesion without a mass, radiologically hidden cancer, or small oval radiopaque mass) (Table 1). The tumor size of AcCC varies from 10 mm to 71 mm, but two independent case series reported that the median size was 19 and 25 mm, respectively [11, 12]. Axillary lymph node metastasis appears to be a rare event in AcCC (Table 1). The largest series
by Zhong et al. (2014) reported no axillary metastases in all eleven included patients [8]. However, local recurrence was reported in several independent case series of AcCC (Table 1). The pattern of distant metastases is similar to that of invasive ductal carcinoma NST, involving lung, liver, and bone [3, 13] and is usually associated with an unfavorable clinical outcome (Table 1). Occasionally, peritoneal metastases may also develop [14] but other common (brain) and unusual visceral metastases (e.g., genitourinary, reproductive tract) have not been reported yet for patients with AcCC.

The therapeutic approach for patients with AcCC has been similar to patients with invasive ductal carcinoma NST (Table 2). The treatment modalities follow the general breast cancer guidelines and include surgery with axillary lymph node dissection (some with sentinel lymph node biopsy); Adjuvant chemo- and radiotherapy were also used, as well as hormonal therapy for the hormone-receptor-positive cases [15-18]. Several patients were also treated with neoadjuvant chemotherapy (Table 2) [7, 14, 15, 17-21]. Given a relatively indolent clinical course in a subset of AcCC (e.g., low-grade cases), these patients should probably be spared chemotherapy [22]; similarly, neoadjuvant chemotherapy should not be a preferable option for AcCC patients due to the predominantly low proliferation rate measured by Ki-67 (Table 3).
Histopathology of AcCC

According to the current World Health Organization classification (WHO) from 2019 [3], AcCC is defined as TNBC and is recognized as a distinct form of salivary gland-type tumor of the breast (Tables 3 and 4). Morphologically, AcCC consists of serous differentiation cells containing zymogenic granules in the cytoplasm. These granules stain positive for Periodic Acid-Schiff (PAS) with diastase (PAS-D) (Figure 2D). It exhibits various growth patterns, with cells arranged in solid and/or microglandular growth patterns (Figure 2A-C) (various growth patterns and morphological features of AcCC are summarized in Table 1). Therefore, recognition of the cytologic features is critical for proper diagnosis. The neoplastic cells have abundant eosinophilic or basophilic granular cytoplasm with centrally located nuclei and prominent nucleoli [3] (Figure 2). The neoplastic cells may occasionally have a clear cytoplasm. Atypia is usually more prominent in solid areas. Mitotic figures may also be seen but are usually not marked. AcCC may be accompanied by invasive ductal carcinoma NST ("mixed" cases), as documented in some studies [11, 23]. In rare cases, AcCC may be associated with metaplastic breast carcinoma [23] or other salivary gland-type tumors such as high-grade/basaloid/forms of adenoid cystic carcinoma. An in situ component may also be present within the AcCC mass, indicating the primary mammary origin of the neoplasm (usually high-grade ductal carcinoma in situ/DCIS/) [3].

Although reported in several studies [reviewed in Limite et al. [24]], the association between AcCC and microglandular adenosis as a precursor lesion is controversial [25-27]. For example, Rosen questions the existence of AcCC as a distinct entity and instead favors the entity "invasive carcinoma with acinic cell differentiation arising in microglandular adenosis" [25]. On the other hand, Geyer et al. have provided molecular evidence that microglandular adenosis and AcCC represent the low-grade spectrum of TNBC lesions with indolent clinical course and
share some molecular features (e.g., TP53 mutations and common copy number alterations, such as gains of 1q, 2q, 7p, and 8q and losses of 3p, 5q, 6q, 14q, 17p, and 17q, Table 3) [26, 27]. Notably, both AcCC and microglandular adenosis share a similar immunophenotype, such as S-100 expression [4]. Occasionally, the difference between AcCC with predominant microglandular growth pattern and microglandular adenosis may also be challenging [13].

Other differential diagnoses of AcCC include invasive carcinomas NST, apocrine carcinomas, and oncocytic carcinomas [3, 13]. Secretory carcinoma may be another mimicker, but it usually has bland nuclear morphology andharbors a balanced t(12;15), causing ETV6-NTRK3 fusion, which is absent in AcCC. Clues for correct diagnosis include cellular features and the presence of intracytoplasmic granules, as well as the expression of biomarkers of serous and acinar differentiation (e.g., lysozyme and α1-antichymotrypsin) [3, 13] (Table 3). In apocrine carcinomas, the status of the androgen receptor (AR) and HER-2/neu, which are positive in all and amplified in 30-50%, respectively, is helpful [28, 29]. Oncocytic carcinoma cells are strongly positive for mitochondrial antibodies and overexpress ER > 50% of cases [3].
Immunohistochemical profile of AcCC

The immunohistochemical characteristics of AcCC are summarized in Tables 2 and 3. AcCC is usually classified as triple-negative breast cancer, meaning that ER, PR, and Her-2/neu are negative (Figure 2E). However, rare cases (~10%) of ER and/or PR-positive AcCC have also been reported [7, 10, 14, 17, 30-34] (Tables 3 and 4). AR is also rarely positive (10%) [35].

Although Her-2/neu expression or HER-2/neu gene amplification is absent in AcCC, the epidermal growth factor receptor (EGFR or HER1) expression has been reported in one study [17]. Other members of the EGFR family (HER3 and HER4) have not been studied at the protein level, but their mutations have been reported (Table 3). Like other epithelial neoplasms, AcCC has positive staining for a broad spectrum of cytokeratins and low-molecular-weight cytokeratins (e.g., CK7 and CK18) (Table 3). Similar to TNBC NST with basal phenotype, high-molecular-weight cytokeratins (e.g., CK5/6) can also be detected in a subset of cases. S-100 and EMA positivity are also consistent features of AcCC, as are markers of serous and acinar differentiation (e.g., lysozyme, 1-anti-chymotrypsin/trypsin, and amylase) (Table 3).

The breast-specific markers GATA3 and GCDFP-15 were detected in ~50% of AcCC (Figure 2F). Despite the limited data, the loss of E-cadherin and ß-catenin proteins has not yet been reported. However, two independent studies have detected mutations of the CTNNBI gene encoding ß-catenin protein [23, 36]. Mutations of the CDH1 gene (encoding E-cadherin) have not been reported previously (Table 4). Interestingly, CTNNBI gene mutations have not been described in salivary AcCC but do occur in pancreatic acinar cell carcinomas [37]. TNBCs are also characterized by the activation of ß-catenin protein (reduced membranous and increased nuclear expression) but without CTNNBI gene mutation [38].
The proliferation rate measured by Ki-67 shows a wide range of positivity (5-71%); however, most studies reported low to moderate Ki-67 expression (range 5-30%), consistent with mitotic activity on H&E slides and the intermediate clinical course of AcCC [3].
Molecular genomic characteristics of AcCC

The molecular genomic characteristics of AcCC in the breast are summarized in Table 4.

Because of its rarity, little information is available on the molecular genomic features of AcCC. Overall, no pathognomonic genomic alterations have been described in the AcCC of the breast. However, molecular studies have shown that mammary AcCC has a similar molecular profile to TNBC [11, 27]; in contrast, molecular features typical of salivary gland AcCC (e.g., recurrent (t[4;9][q13;q31]) genomic rearrangement) are generally absent in its mammary counterparts. Thus, TP53 mutations appear to be the most consistent molecular event in AcCC; other genetic alterations (e.g., PIK3CA mutations) have also been described in a subset of cases [11, 23, 27]. BRCA1 gene alterations (mutations and gene deletions) also characterize some breast AcCC [16, 23, 27, 36]. Beca et al. performed whole-exome and RNA sequencing in three AcCC cases and reported mutations in genes related to homologous recombination and DNA repair in two AcCC cases and a pathogenic MLH1 germline mutation in the third AcCC case [36]. Guerini-Rocco et al. (2015) studied eight cases (two pure AcCC and six mixed), used massively parallel sequencing (panel of 254 genes), and performed further validation by targeted amplicon and Sanger sequencing on microdissected samples. They found identical genomic alterations in AcCC-only and mixed cases (Table 4) [23]. Piscuoglio et al. [11] performed a comparative molecular study (breast carcinoma vs. salivary AcCC) with Sanger sequencing to investigate the frequency of TP53 and PIK3CA mutations in two cohorts. Consistent with the TNBC profile, only mammary AcCC had TP53 (80%) and PIK3CA (10%) mutations, whereas all twenty salivary AcCC had no somatic mutations in these two genes [11]. In another comparative study, Geyer et al. explored molecular genomic features of AcCC and microglandular adenosis of the breast. They reported similar genomic alterations in the two breast...
lesions (e.g., TP53, BRCA1, PIK3CA, and INPP4B) (Table 4) [27]. The repertoire of somatic mutations in both lesions was comparable to TNBC NST. Both lesions had multiple and complex gene copy changes, including gains of 1q, 2q, 7p, and 8q and losses of 3p, 5q, 6q, 14q, 17p, and 17q. However, loss of 16q in the entire arm was not found, consistent with high-grade TNBC NST. Amplifications within the 8q region were detected in both cohorts (affecting FSBP, EPPK1, MYC, SLA, and COL14A1) [27]. The authors concluded that both tumors represent a spectrum of "low-grade forms of TNBC with no/low metastatic potential", although some have the potential to progress to high-grade forms of TNBC [27].

Recurrent genomic rearrangement [t(4;9)(q13;q31)], which allows upregulation of the transcription factor Nuclear Receptor Subfamily 4 Group A Member 3 (NR4A3), has been described as an oncogenic driver event in salivary AcCC [39]. Several studies have shown that NR4A3 is an excellent diagnostic biomarker with high sensitivity and specificity in detecting salivary gland AcCC [40-43]. In addition, Owosho et al. (2021) demonstrated a higher diagnostic utility of NR4A3 compared with DOG1 immunostaining for salivary gland AcCC [43]. No study has yet reported on the NR4A3 status for AcCC of the breast, though Waever et al. (2021) have reported DOG1 expression in one case of mammary AcCC [19]. The fact that t(12;15) (ETV6/NTRK3 translocation) typical of secretory carcinomas is not present in the AcCC of the breast [44] suggests that this finding might be useful for differential diagnosis in cases with overlapping or similar morphology.
Novel treatment options for AcCC patients

In addition to attempting neo-adjuvant and adjuvant chemotherapy (e.g. with adriamycin, cyclophosphamide, methotrexate and 5-fluorouracil (Table 2), the unique molecular and genomic profile of mammary AcCC might also allow for potential targeted therapies in these patients—though clinical information on this topic in the literature is limited. Similar to TNBC NST, BRCA1 mutations have been reported in a subset of AcCC and mutations in genes related to homologous recombination and DNA repair and MLH1 [36] (Table 4). Consequently, these patients may be viable candidates for treatment with poly(ADP-ribose) polymerase (PARP) inhibitors (PARPi) such as olaparib and talazoparib—both of which are already approved for metastatic breast cancer patients housing germline BRCA1 mutations and HER2-negative tumors [45, 46].

Dysregulation of the phosphoinositide 3 (PI3)-kinase/Akt signaling pathway including through activating PIK3CA mutations, that are among the most common genetic alterations in breast cancer, particularly in luminal breast tumors [47], is associated with increased cancer cell growth, proliferation and survival. The PIK3CA inhibitor alpelisib is a p110α-specific PI3K inhibitor that has a better safety profile than non-specific PI3K inhibitors. The U.S. Food and Drug Administration (FDA) has already approved its use in combination with fulvestrant for treating postmenopausal women with ER+/HER2-, PIK3CA-mutated breast cancer that has progressed after hormone therapy [48]. PIK3CA and/or AKT1 mutations are also detectable in ~25-30% of advanced TNBC NST and special types such as metaplastic breast carcinoma [49, 50]. Recent clinical data also indicate a potential effect of targeted treatment for these breast cancer patients [51, 52]. Given that a small proportion of mammary AcCC also has activating PIK3CA gene mutations, PIK3CA inhibitors should be considered as a treatment option for patients with
advanced/or refractory disease.

The PI3K/Akt signaling pathway also acts as a downstream effector of the EGFR family of receptor tyrosine kinases in regulating cell growth, proliferation and survival [53]. The fact that some breast AcCC are reported to be EGFR positive (see Table 3), might imply that clinically-approved EGFR inhibitors, either as small molecule tyrosine kinase inhibitors like gefitinib or monoclonal antibodies like cetuximab, might also be indicated for these patients.

The immune checkpoint inhibitor pembrolizumab (Keytruda®, Merck) and predictive companion diagnostic (CDx) test (PD-L1 expression by immunohistochemistry, defined as Combined Positive Score [CPS] ≥10) have been approved for both high-risk early-stage TNBC and locally recurrent, unresectable/metastatic tumors [54]. In contrast to salivary glands AcCC [55], no study has reported PD-L1 receptor status in mammary AcCC. Similarly, the status of another predictable biomarker, tumor mutation burden (TMB) in breast AcCC remains unknown. Thus, in the absence of PD-L1 expression, the use of checkpoint inhibitors in mammary AcCC patients at this stage is not warranted.

In summary, several molecular targets observed in AcCC might lend themselves to potential targeted therapies with already clinically approved drugs that could also provide improved clinical outcomes in patients with this rare carcinoma.
Conclusions

Our comprehensive literature review confirms the rarity of mammary acinic cell carcinoma. Its clinical and radiologic features are similar to invasive ductal carcinoma NST, while its morphology may have various growth patterns. However, the cytologic features are specific because the cells contain zymogenic granules in the cytoplasm. Acinic cell carcinomas usually exhibit a triple-negative phenotype and less aggressive clinical behavior than the NST subtype. Molecular genomic features are similar to TNBC NST but are significantly different from AcCC arising in the salivary glands, which harbor a characteristic fusion. Based on the presence of CTNNBI mutations in mammary AcCC, this tumor may be closer to the pancreatic counterpart than to the salivary-type malignancy or TNBC. Biomarkers for targeted treatment are currently limited, although a few studies have identified potentially targetable biomarkers (e.g., BRCA, PIK3CA). These molecular targets may guide tailored therapeutics for individual cases with advanced/or refractory forms of acinic cell carcinoma.
Conflict of Interest

The authors declare no conflict of interest.
### Tables

**Table 1.** A summary of clinical and histopathologic characteristics of the acinic cell carcinoma of the breast. The studies were identified through a comprehensive literature search in the major databases (PubMed/MEDLINE, Scopus, and Web of Science Core Collection).

| Author (year) | Sex/Age | Site | Tumor size (mm) | Growth pattern | Radiographic features | Node status | Follow up (months) | Recurrences/Metastases/Outcome |
|---------------|---------|------|-----------------|----------------|-----------------------|-------------|-------------------|---------------------------------|
| 1 Sarsiat et al. (2022)[14] | F/59 | R | 71 | Solid and microglandular | Mammography: An ill-defined solid lesion. | 0/2 | 49 | Peritoneal metastases/DOD |
| 2 Yu et al. | F/49 | L | 35 | Solid and microglandular | Mammography: Occult cancer. Mammography: Detected during screening | 0/3 | 0/3 |
| 3 (2022)[56] | F/42 | R uoq | 30 | Solid, microglandular and pseudolobular | | |
| 4 Waever et al. | F/42 | L | 60 | Solid, microlobular and pseudolobular | Ultrasonography: Well-defined, lobulated, solid lesion with characteristics of a fibroadenoma | | 48 | NED |
| 5 Sen et al. | F/41 | R uoq | 25 | Acinar and solid | Ultrasonography and mammography: No abnormalities. | 0 | 12 | NED |
| Study | Sex | Age | Laterality | Histology | Mammography | Ultrasonography | Follow-up |
|-------|-----|-----|------------|-----------|-------------|-----------------|-----------|
| Li et al. (2017) [30] | F/52 | L luq | 15 | Cystic and cribriform | 0/1 | 3 | AW |
| Kim et al. (2017) [58] | F/38 F/47 F/60 | L L L | 0/1 | | 0 | 1a | NED NED NED |
| Kawai et al. (2016) [59] | F/49 | R | 35 | Solid-trabecular and acinar | Mammography: Lobulated mass with poorly defined margins, without microcalcifications | 8 | DR |
| Xu et al. (2016) [20] | F/41 | R uoq | 12 | Acinar-glandular and solid | Mammography: A small oval radiopaque mass | 13 | |
| Sherwell-Cabello et al. (2016) [60] | F/38 | | | Microglandular | | | NED |
| Conlon et al. (2016) [7] | F/47 F/49 | R luq R uoq | 23 11 | Microglandular and solid | Mammography: Occult | 1/18 0 | 72 18 | DR/ Alive with disease NED |
| Study                                | Pathology                      | Age | Sex | Histology | TNM | Clinical Outcome |
|--------------------------------------|--------------------------------|-----|-----|-----------|-----|------------------|
| Guerini et al. (2015)[23]            | Clear cell Microglandular      | 50  | F/36| Microglandular | 10/17 | DOD             |
|                                      | Microglandular                 | 19  | F/55| Microglandular | 0/8   | NOD             |
|                                      | Microglandular                 | 11  | F/34| Microglandular | 0/3   | NED             |
|                                      | Microglandular                 | 36  | F/42| Microglandular | 0/3   | NED             |
|                                      | Microglandular                 | 20  | F/34| Microglandular | 0/3   | NED             |
|                                      | Microglandular                 | 14  | F/48| Microglandular | 0/3   | NED             |
|                                      | Microglandular                 | 18  | F/70| Microglandular | 0/3   | NED             |
|                                      | Microglandular                 | 18  | F/35| Microglandular | 0/3   | NED             |
| Piscuoglio et al. (2015)[11]         | Microglandular                 | 15  | F/49| Microglandular | 0/3   | NED             |
|                                      | Microglandular                 | 21  | F/45| Microglandular | 0/3   | NED             |
| Zhong et al. (2014)[8]               | Microglandular                 | 15  | F/50| Microglandular | 0/3   | NED             |
|                                      | Microglandular                 | 16  | F/40| Microglandular | 0/3   | NED             |
|                                      | Microglandular                 | 30  | F/59| Microglandular | 0/3   | NED             |
|                                      | Microglandular                 | 17  | F/42| Microglandular | 0/3   | NED             |
|                                      | Microglandular                 | 30  | F/56| Microglandular | 0/3   | NED             |
|                                      | Solid, microglandular and solid| 28  | F/42| Microglandular | 0/3   | NED             |
|                                      | Microglandular                 | 50  | F/50| Microglandular | 0/3   | NED             |
|                                      | Acinic-glandular and solid     | 15  | F/61| Microglandular | 0/3   | NED             |
|                                      | Acinic-glandular and solid     | 18  | F/35| Microglandular | 0/3   | NED             |
|                                      | Acinic-glandular and solid     | 25  | F/34| Microglandular | 0/3   | NED             |
|                                      | Acinic-glandular and solid     | 30  | F/46| Microglandular | 0/3   | NED             |
| Limite et al. (2014)[24]             | Acinic-glandular and solid     | 16  | F/26| R lqu      | 0/1   | 8               |
| Falleti et al. (2013)[32]            | Solid, microglandular and microacinar | 30 | R peri-areolar | 0/1 | 10 | AW          |
| Study          | Age | Side | Lesion Type/Location                     | MRI Description                                                                 | Size | Tumor Type | Follow-up |
|---------------|-----|------|-----------------------------------------|---------------------------------------------------------------------------------|------|------------|-----------|
| Osako et al. 39 (2013)[61] | F/50 F/37 F/46 | 52 22 50 | Microglandular Microglandular and solid Papillary, microglandular, solid and cystic | 0/30 0/23 0/4 | 184.8 139.2 64.8 | NED NED NED |
| Shingu et al. (2013)[62] | F/41 | L loq | Solid, trabecular and microglandular | Mammography: Focal asymmetric density of the breast. Ultrasonography: A heterogeneous hypoechoic mass with ill-defined margins. MRI: High-intensity mass, but no intraductal dissemination. | 0/1 | 36 | NED |
| Winkler et al. (2013)[15] | F/56 | R | Solid | MRI: Heterogeneous segmental non-mass-like enhancement extending toward the nipple in a triangular configuration. | 0/1 | 24 | NED |
| Zhao et al. (2014)[12] | F/38 | R uoq | Microglandular | | 0/23 | 10 | NED |
| Ripamonti et al. (2013)[16] | F/44 | L uoq | Microglandular | MRI: Solid mass with pushing borders. | 0/2 | 19 | AW |
| Choh et al. (2012)[63] | F/79 | L upper pole | 27 | | 0/1 | 9 | NED |
| Sakuma et al. F/61 | R uoq | 14 | Solid and microcystic | Mammography: Dense, | 0 | 14 | NED |
| Reference | Sex | Age | Histology | Ultrasound/Mammography | Follow-up | Prognosis |
|-----------|-----|-----|-----------|-------------------------|-----------|-----------|
| al. (2013)[31] | | | inhomogeneous parenchyma; Ultrasonography: A hypoechoic, irregularly shaped mass with ill-defined borders. | | | |
| 47 Chang et al. (2011)[64] | F | 39 | 55 | Acinar/glandular and solid | Ultrasonography and mammography: No abnormalities. | 1 | Unfavorable prognosis |
| 48 Huo et al. (2011)[17] | R | 36 | Microglandular, solid and focally microcystic Microglandular Microglandular | | | |
| 49 | L | 21 | | | | |
| 50 | | | | | | |
| 51 Stolnicu et al. (2010)[35] | L | 25 | Solid, microcystic, microglandular and trabecular | Ultrasonography and mammography: Malignant features (no details provided). | 10/15 | 9 | AW |
| 52 Matoso et al. (2009)[65] | L | | Amphophilic cytoplasm with zymogen-like secretory granules | | | |
| 53 Tanahashi et al. (2007)[33] | R | 21 | Acinar | Ultrasonography: A hypoechoic nodule with a smooth surface. Mammography: A well-demarcated mass. No microcalcifications. | 0/1 | 22 | AW |
| 54 Peintinger et al. (2004)[66] | R | 35 | Solid and microglandular | | 0/15 | 120 | Lung metastasis/ NED 12 months after surgery |
| Patient Details | Lesion Details | Follow-up | Outcome |
|----------------|---------------|-----------|---------|
| Kahn et al. (2003)[67] | F/56 L 22 Solid | 0/18 | NED |
| Hirokawa et al. (2002) [34] | F/20 R 27 Papillary/cystic | 0 | AW |
| | F/61 L 25 Papillary/cystic, microcystic and follicular | 0 | NED |
| | F/59 R 10 Microfollicular | 0 | NED |
| Coyne et al. (2002) [21] | F/49 R 20 Microglandular | 2/11 | Liver metastasis/ DOD |
| Damiani et al. (2000) [18] | F/42 R uoq 30 Solid | 1/18 | AW |
| | F/35 R uoq 40 Microglandular | 2/20 | AW |
| | F/63 L 50 Microglandular | 0/8 | Lost |
| | F/55 L 20 Microglandular | 12 | AW |
| | F/64 L uq 33 Microglandular | 12 | AW |
| | F/80 R uoq 20 Microglandular | 12 | AW |
| Schmitt et al. (2000)[68] | F/79 L uq 45 Solid | 0/23 | NED |
| Shimao et al. (1998) [10] | M/23 L 48 Solid | 34 | NED |
| Study | Gender | Age | Stage | Type | Description | Year | Age at Diagnosis | Status |
|-------|--------|-----|-------|------|-------------|------|------------------|--------|
| 68 Roncaroli et al. (1996)[6] | F/42 | R uoq | 30 | Solid | Mammography: A mass with well-defined margins with scattered granular calcifications. | 1/18 | 60 | AW |

F – female; M – male; AW-Alive and well; DOD-Died of disease, DR-disease recurrence, ioq-inferior outer quadrant; L-left; loq-lower outer quadrant; lqu-lower quadrant union; R-right; NED-no evidence of disease, uiq-upper internal quadrant; uoq-upper outer quadrant
Table 2. Overview of the reported treatment modalities used for the treatment of acinic cell carcinoma of the breast.

| Author (year)         | Surgery          | Adjuvant therapy |
|-----------------------|------------------|------------------|
| 1 Sarsiat et al.      | BCS + SLND       | Neo-CT           |
| (2022)[14]            |                  |                  |
| 2 Yu et al. 3 (2022)[56] | MRM + SLND | BCS + SLND | - |
| 4 Waever et al.       | Mastectomy + SLND | Neo-CT           |
| (2021)[19]            |                  |                  |
| 5 Sen et al. (2018)[57] | MRM + ALND |                  | - |
| 6 Li et al. (2017)[30] | Mastectomy       |                  | - |
| 7 Kim et al. 8 (2017)[58] | BCS           | CT + RT          |
| 9                     | BCS             | CT + RT          |
|                       | BCS             | -                |
| Study Reference | Treatment Details | Follow-Up |
|-----------------|-------------------|----------|
| 10 Kawai et al. (2016)[59] | MRM + SLND | CT |
| 11 Xu et al. (2016)[20] | BCS | Neo-CT |
| 12 Sherwell-Cabello et al. (2016) [60] | na | na |
| 13 Conlon et al. (2016)[7] | B/L mastectomy + ALND BCS CT | Neo-CT |
| 15 Guerini et al (2015)[23] | na | na |
| 23 Piscuoglio et al. (2015)[11] | na | na |
| 25 Zhong et al. (2014)[8] | BCS BCS Mastectomy BCS Mastectomy Mastectomy Mastectomy Mastectomy BCS Mastectomy Mastectomy Mastectomy | CT + RT CT + RT CT CT + RT CT CT CT CT CT + RT CT |
| 35 | Mastectomy | CT |
|----|-------------|----|
| 36 Limite et al. (2014)[24] | BCS + SLND | - |
| 37 Falleti et al. (2013)[32] | BCS + SLND | - |
| 38 Osako et al. 39 (2013)[61]40 | MRM + ALND | - |
|  | BCS + ALND | - |
|  | MRM + SLND | - |
| 41 Shingu et al. (2013)[62] | BCS + SLND | CT + RT |
| 42 Winkler et al. (2013)[15] | MRM + SLND | Neo-CT+ HT |
| 43 Zhao et al. (2014)[12] | MRM + ALND | CT |
| 44 Ripamonti et al. (2013)[16] | MRM + SLND | HT |
| 45 Choh et al. (2012)[63] | BCS + SLND | RT |
| 46 Sakuma et al. (2013)[31] | BCS + ALND | - |
| 47 Chang et al. (2011)[64] | BCS + ALND | - |
| 48 Huo et al. | MRM + ALND | Neo-CT + RT + HT |
|   | Authors                        | Treatment               | Follow-up       |
|---|-------------------------------|-------------------------|----------------|
| 49 | Stolnicu et al. (2010)        | BCS + ALND              | CT + RT        |
|   |                               | BCS + SLND              |                |
| 50 |                               |                         |                |
| 51 | Stolnicu et al. (2010)        | MRM + ALND              | -              |
| 52 | Matoso et al. (2009)          | na                      | na             |
| 53 | Tanahashi et al. (2007)       | MRM + SLND              | -              |
| 54 | Peintinger et al. (2004)      | BCS + ALND              | CT + RT        |
| 55 | Kahn et al. (2003)            | MRM + ALND              | -              |
| 56 | Hirokawa et al. (2002)        | MRM + ALND              | -              |
| 57 | T. Hirokawa et al. (2002)     | MRM + ALND              | -              |
| 58 |                               | MRM + ALND              | -              |
| 59 | Coyne et al. (2002)           | MRM + ALND              | Neo-CT + CT    |
| 60 | Damiani et al. (2000)         | MRM                     | CT             |
| 61 |                              | MRM + ALND              | Neo-CT         |
| 62 |                              | BCS                     | -              |
| 63 |                              | BCS                     | -              |
| 64 |                              | BCS + ALND              | -              |
| 65 |                              | BCS                     | HT             |
| 66 | Schmitt et al. (2000)         | MRM + ALND              | RT             |
| al. (2000)[68] | 67 Shimao et al. (1998) [10] | BCS + ALND | - |
|----------------|---------------------------------|------------|---|
| 68 Roncaroli et al. (1996)[6] | MRM + ALND | CT |

ALND – Axillary lymph node dissection; BCS – Breast-conserving surgery; B/L – Bilateral; CT – Chemotherapy (adjuvant); HT – Hormone therapy; MRM – Modified radical mastectomy; Neo-CT – Neoadjuvant chemotherapy; RT – Radiation therapy; na – Not available; SLND – Sentinel lymph node dissection
Table 3. Summary of the immunohistochemical features reported in the literature on mammary acinic cell carcinoma.

| Immunohistochemical biomarker | Positivity, % (number of cases/total cases) |
|------------------------------|---------------------------------------------|
| **Steroid receptors**        |                                             |
| Estrogen receptor            | 10 (7/66)                                   |
| Progesterone receptor        | 11 (7/62)                                   |
| Androgen receptor            | 10 (1/10)                                   |
| **Growth factor receptors**  |                                             |
| HER-2/neu                    | 0 (0/54)                                    |
| EGFR                         | 67 (2/3)                                    |
| **Cytokeratins**             |                                             |
| panCK                        | 100 (11/11)                                 |
| LMW-CK                       | 100 (1/1)                                   |
| HMW-CK                       | 0 (0/1)                                     |
| CK5/6                        | 50 (3/6)                                    |
| CK7                          | 100 (9/9)                                   |
| CK14                         | 0 (0/1)                                     |
| CK18                         | 100 (1/1)                                   |
| CK20                         | 0 (0/2)                                     |
| **Other biomarkers**         |                                             |
| Ki-67                        | Range: 5-71% (most studies: 5-30%)          |
| E-cadherin                   | 100 (7/7)                                   |
| Beta-catenin                 | 100 (1/1)                                   |
| Lysozyme                     | 95 (39/41)                                  |
| Amylase                      | 94 (17/18)                                  |
| α1-1-ACT                     | 96 (25/26)                                  |
| GATA3                        | 50 (2/4)                                    |
| GCDFP-15                     | 56 (14/25)                                  |
| S-100                        | 93 (50/54)                                  |
|     |     |
|-----|-----|
| EMA | 100 (29/29) |
| SMA | 0 (0/14) |

$\alpha_1$-ACT - $\alpha_1$ anti-chymotrypsin/trypsin; CK – Cytokeratin; EGFR – Epidermal growth factor receptor; EMA – Epithelial membrane antigen; GDCDFP-15 – Gross cystic disease fluid protein; HER2 – Human epidermal growth factor receptor; HMW – High molecular weight; LMW – Low molecular weight; SMA – Smooth muscle actin
Table 4. Overview of the studies exploring molecular genetic characteristics of acinic cell carcinoma of the breast.

| Author (year)                  | Cases | Method(s)                                | Steroid receptors and HER-2/neu status | Molecular features (frequency)                                                                 |
|--------------------------------|-------|------------------------------------------|---------------------------------------|-------------------------------------------------------------------------------------------------|
| Waever et al. (2021)[19]       | 1     | IHC, NGS                                 | Triple-negative                        | DOG1 positive, GATA3 positive TP53, RET SNV mutation                                           |
| Beca et al. (2019)[36]         | 3     | WES, RNA sequencing                      | Triple-negative (3/3)                  | TC2N-FBLN5 (2/3), TP53 (2/3), MLH1 (1/3), CTNNB1 (1/3), a BRCA1 homozygous deletion (1/3), high-level amplification of 12q14.3–12q21.1 in MDM2, HMG2A2, WIF1, FRS2, PTPR8B (1/3), focal amplification in 20p12.3 encompassing PCNA (1/3) |
| Geyer et al. (2017)[27]        | 8     | IHC, massively parallel sequencing       | Triple-negative (8/8)                  | Lysozyme (8/8)*, TP53 (7/8)*, ERBB4 (2/8)*, ERBB3 (1/8)*, FGFR2 (1/8)*, PIK3CA (1/8)*, INPP4B (1/8)*, Complex and multiple genomic alterations: Gains of 1q, 2q, 7p, and 8q and losses of 3p, 5q, 6q, 14q, 17p and 17q |
| Conlon et al. (2016)[7]        | 2     | IHC, NGS                                 | ER(-), PR (+), HER2 (-) (I); ER (-), PR (-), HER2 (-) (II) | α1-ACT (2/2), lysozyme (2/2), GCDFP-15 (1/2) TP53 (1/2), MLL3 (1/2), TSC2 (1/2) |
| Guerini-Rocco et al. (2015)[23]* | 8     | IHC, massively parallel sequencing       | Triple-negative (8/8)                  | Lysozyme (8/8), Ki-67 (11-27%) TP53 (7/8), KMT2D (2/8), NEB (2/8), EPPK1 (2/8), CUBN (1/8) INPP4B (1/8), FGFR2 (1/8), PIK3CA (1/8), CTNNB1 (1/8), PGR (1/8), ERBB4 (2/8), ERBB3 (1/8), BRCA1 (1/8) |
| Study                          | n  | Method                        | TN Status            | Genetic Findings                       |
|-------------------------------|-----|-------------------------------|----------------------|----------------------------------------|
| Piscuoglio et al. (2015)[11]* | 10  | PCR amplification, Sanger    | Triple-negative (10/10) | TP53 (8/10), E542K PIK3CA (1/10)       |
| Ripamonti et al. (2013)[16]   | 1   | IHC, DNA sequencing           | Triple-negative      | EMA positive, GCDFP-15 positive, BRCA1 and TP53 mutated |
| Reis-Filho et al. (2008)[44]  | 6   | FISH                          | Triple-negative (6/6) | Negative for t(12;15) (ETV6/NTRK3 translocation) |

α1-ACT – α1-antichymotrypsin; EMA – Epithelial membrane antigen; ER – Estrogen receptor; FISH – Fluorescent in situ hybridization; GCDFP-15 – Gross cystic disease fluid protein 15; HER2 – Human epidermal growth factor receptor; IHC – Immunohistochemistry; NGS - Next-generation sequencing; NTRK – Neurotrophic Tyrosine Receptor Kinase; PCR – Polymerase chain reaction; PR – Progesterone receptor; SNV – Single-nucleotide variant; WES – Whole-exome sequencing

*The same samples were used.
Figures

**Figure 1.** A flowchart shows the literature search approach for identifying and analyzing acinic cell carcinoma studies.

**Figure 2A-F.** Hematoxylin and Eosin (H&E) slides of a case of acinic cell carcinoma of the breast with different growth patterns, including acinar (A), microglandular (B), and solid (C) growth patterns. Image D shows PAS positivity in tumor cells, while estrogen receptor (E), and GATA3 (F) are negative [69].
References

[1] Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2022. CA Cancer J Clin. 2022;72:7-33.
[2] Cancer Genome Atlas N. Comprehensive molecular portraits of human breast tumours. Nature. 2012;490:61-70.
[3] Board WCoTE. WHO Classification of Breast Tumours. Lyon: IARC; 2019.
[4] Pareja F, Weigelt B, Reis-Filho JS. Problematic breast tumors reassessed in light of novel molecular data. Mod Pathol. 2021;34:38-47.
[5] Pia-Foschini M, Reis-Filho JS, Eusebi V, Lakhani SR. Salivary gland-like tumours of the breast: surgical and molecular pathology. J Clin Pathol. 2003;56:497-506.
[6] Roncaroli F, Lamovec J, Zidar A, Eusebi V. Acinic cell-like carcinoma of the breast. Virchows Arch. 1996;429:69-74.
[7] Conlon N, Sadri N, Corben AD, Tan LK. Acinic cell carcinoma of breast: morphologic and immunohistochemical review of a rare breast cancer subtype. Hum Pathol. 2016;51:16-24.
[8] Zhong F, Bi R, Yu B, Cheng Y, Xu X, Shui R, et al. Carcinoma arising in microglandular adenosis of the breast: triple negative phenotype with variable morphology. Int J Clin Exp Pathol. 2014;7:6149-56.
[9] Zhang S, Huang S, Zhang H, Li D, Li X, Cheng Y, et al. Histo- and clinico-pathological analysis of a large series of triple-negative breast cancer in a single center in China: Evidences on necessity of histological subtyping and grading. Chin J Cancer Res. 2020;32:580-95.
[10] Shimao K, Haga S, Shimizu T, Imamura H, Watanabe O, Kinoshita J, et al. Acinic Cell Adenocarcinoma Arising in the Breast of a Young Male: A Clinicopathological, Immunohistochemical and Ultrastructural Study. Breast Cancer. 1998;5:77-81.
[11] Piscuoglio S, Hodi Z, Katabi N, Guerini-Rocco E, Macedo GS, Ng CK, et al. Are acinic cell carcinomas of the breast and salivary glands distinct diseases? Histopathology. 2015;67:529-37.
[12] Zhao Y, Li W, Lang R, Yang Y, Gao X, Zheng Y, et al. Primary acinic cell carcinoma of the breast: a case report and review of the literature. Int J Surg Pathol. 2014;22:177-81.
[13] Foschini MP, Morandi L, Asiolli S, Giove G, Corradini AG, Eusebi V. The morphological spectrum of salivary gland type tumours of the breast. Pathology. 2017;49:215-27.
[14] Sarsiatis L, Watkinson G, Turnbull A, Diana A, Oikonomidou O. Primary acinic cell carcinoma of the breast is associated with a poor outcome: A case report and literature review. Mol Clin Oncol. 2022;16:43.
[15] Winkler N, Morrell G, Factor RE. Invasive carcinoma with acinic cell-like features of the breast. Breast J. 2013;19:334-5.
[16] Ripamonti CB, Colombo M, Mondini P, Siranoush M, Peissel B, Bernard L, et al. First description of an acinic cell carcinoma of the breast in a BRCA1 mutation carrier: a case report. BMC Cancer. 2013;13:46.
[17] Huo L, Bell D, Qiu H, Sahin A, Wu Y, Sneige N. Paneth cell-like eosinophilic cytoplasmic granules in breast carcinoma. Ann Diagn Pathol. 2011;15:84-92.
[18] Damiani S, Pasquinelli G, Lamovec J, Peterse JL, Eusebi V. Acinic cell carcinoma of the breast: an immunohistochemical and ultrastructural study. Virchows Arch. 2000;437:74-81.
[19] Weaver KD, Isom J, Esnakula A, Daily K, Asirvatham JR. Acinic Cell Carcinoma of the Breast: Report of a Case With Immunohistochemical and Next-Generation Sequencing Studies. Int J Surg Pathol. 2021;29:882-6.
[20] Xu J WQ, Qi Y, Zhao R, Wan Y, Ji Y, Zou X. Primary breast acinic cell carcinoma and concurrent carcinoma arising from microglandular adenosis. Int J Clin Exp Pathol 2016;9:5792-6.
[21] Coyne JD, Dervan PA. Primary acinic cell carcinoma of the breast. J Clin Pathol. 2002;55:545-7.
[22] Cserni G, Quinn CM, Foschini MP, Bianchi S, Callagy G, Chmielik E, et al. Triple-Negative Breast Cancer Histological Subtypes with a Favourable Prognosis. Cancers (Basel). 2021;13.
[23] Guerini-Rocco E, Hodi Z, Piscuoglio S, Ng CK, Rakha EA, Schultheis AM, et al. The repertoire of somatic genetic alterations of acinic cell carcinomas of the breast: an exploratory, hypothesis-generating study. J Pathol. 2015;237:166-78.
[24] Limite G, Di Micco R, Esposito E, Sollazzo V, Cervotti M, Pettinato G, et al. Acinic cell carcinoma of the breast: review of the literature. Int J Surg. 2014;12 Suppl 1:S35-9.
[25] Rosen PP. So-called acinic cell carcinoma of the breast arises from microglandular adenosis and is not a distinct entity. Mod Pathol. 2017;30:1504.
[26] Reis-Filho JS, Geyer FC, Weigelt B, Rakha EA, Ellis IO, Schnitt SJ. Reply to Rosen. Mod Pathol. 2017;30:1505-6.
[27] Geyer FC, Berman SH, Marchio C, Burke KA, Guerini-Rocco E, Piscuoglio S, et al. Genetic analysis of microglandular adenosis and acinic cell carcinomas of the breast provides evidence for the existence of a low-grade triple-negative breast neoplasia family. Mod Pathol. 2017;30:69-84.
[28] Vranic S, Gatalica Z. An Update on the Molecular and Clinical Characteristics of Apocrine Carcinoma of the Breast. Clin Breast Cancer. 2022;22:e576-e85.
[29] Vranic S, Feldman R, Gatalica Z. Apocrine carcinoma of the breast: A brief update on the molecular features and targetable biomarkers. Bosn J Basic Med Sci. 2017;17:9-11.
[30] Li H, Wang F, Shen P, Zhou F. Pure acinic cell carcinoma of the breast: A case report and literature review. Medicine (Baltimore). 2017;96:e8866.
[31] Sakuma T, Mimura A, Tanigawa N, Takamizu R. Fine needle aspiration cytology of acinic cell carcinoma of the breast. Cytopathology. 2013;24:403-5.
[32] Falleti J, Coletti G, Rispoli E, Scarabeo F, Cervasio M, Tornillo L, et al. Acinic cell carcinoma of the breast arising in microglandular adenosis. Case Rep Pathol. 2013;2013:736048.
[33] Tanahashi C, Yabuki S, Akamine N, Yatabe Y, Ichihara S. Pure acinic cell carcinoma of the breast in an 80-year-old Japanese woman. Pathol Int. 2007;57:43-6.
[34] Hirokawa M, Sugihara K, Sai T, Monobe Y, Kudo H, Sano N, et al. Secretory carcinoma of the breast: a tumour analogous to salivary gland acinic cell carcinoma? Histopathology. 2002;40:223-9.
[35] Stolnicu S DM, Preda O, et al. Primary acinic cell carcinoma of the breast associated with an intraductal acinic cell component. Patol Rev Latinoam. 2010;48:204-7.
[36] Beca F, Lee SSK, Pareja F, Da Cruz Paula A, Selenica P, Ferrando L, et al. Whole-exome sequencing and RNA sequencing analyses of acinic cell carcinomas of the breast. Histopathology. 2019;75:931-7.
[37] Furukawa T, Sakamoto H, Takeuchi S, Ameri M, Kuboki Y, Yamamoto T, et al. Whole exome sequencing reveals recurrent mutations in BRCA2 and FAT genes in acinar cell carcinomas of the pancreas. Sci Rep. 2015;5:8829.
[38] Geyer FC, Lacroix-Triki M, Savage K, Arnedos M, Lambros MB, MacKay A, et al. beta-Catenin pathway activation in breast cancer is associated with triple-negative phenotype but not with CTNNB1 mutation. Mod Pathol. 2011;24:209-31.
[39] Haller F, Skalova A, Ihrler S, Markl B, Bieg M, Moskalev EA, et al. Nuclear NR4A3 Immunostaining Is a Specific and Sensitive Novel Marker for Acinic Cell Carcinoma of the Salivary Glands. Am J Surg Pathol. 2019;43:1264-72.
[40] Xu B, Saliba M, Ho A, Viswanathan K, Alzumaili B, Dogan S, et al. Head and Neck Acinic Cell Carcinoma: A New Grading System Proposal and Diagnostic Utility of NR4A3 Immunohistochemistry. Am J Surg Pathol. 2022.
[41] Viswanathan K, Beg S, He B, Zhang T, Cantley R, Lubin DJ, et al. NR4A3 Immunostain Is a Highly Sensitive and Specific Marker for Acinic Cell Carcinoma in Cytologic and Surgical Specimens. Am J Clin Pathol. 2022;157:98-108.
[42] Skaugen JM, Seethala RR, Chiosea SI, Landau MS. Evaluation of NR4A3 immunohistochemistry (IHC) and fluorescence in situ hybridization and comparison with DOG1 IHC for FNA diagnosis of acinic cell carcinoma. Cancer Cytopathol. 2021;129:104-13.
[43] Owosho A, Tyler D, Adesina O, Odujoko O, Summersgill K, NR4A3 (NOR-1) Immunostaining Shows Better Performance than DOG1 Immunostaining in Acinic Cell Carcinoma of Salivary Gland: a Preliminary Study. J Oral Maxillofac Res. 2021;12:e4.
[44] Reis-Filho JS, Natrajian R, Vatcheva R, Lambros MB, Marchio C, Mahler-Araujo B, et al. Is acinic cell carcinoma a variant of secretory carcinoma? A FISH study using ETV6'split apart' probes. Histopathology. 2008;52:840-6.
[45] Tung N, Garber JE. PARP inhibition in breast cancer: progress made and future hopes. NPJ Breast Cancer. 2022;8:47.
[46] Cortesi L, Rugo HS, Jackisch C. An Overview of PARP Inhibitors for the Treatment of Breast Cancer. Target Oncol. 2021;16:255-82.
[47] Martinez-Saez O, Chic N, Pascual T, Adamo B, Vidal M, Gonzalez-Farre B, et al. Frequency and spectrum of PIK3CA somatic mutations in breast cancer. Breast Cancer Res. 2020;22:45.
[48] FDA approves alpelisib for metastatic breast cancer. 2019.
[49] Vranic S, Stafford P, Palazzo P, Skenderi F, Swensen J, Xiu J, et al. Molecular Profiling of the Metaplastic Spindle Cell Carcinoma of the Breast Reveals Potentially Targetable Biomarkers. Clin Breast Cancer. 2020;20:326-31 e1.
[50] Joneja U, Vranic S, Swensen J, Feldman R, Chen W, Kimbrough J, et al. Comprehensive profiling of metaplastic breast carcinomas reveals frequent overexpression of programmed death-ligand 1. J Clin Pathol. 2017;70:255-9.
[51] Pascual J, Turner NC. Targeting the PI3-kinase pathway in triple-negative breast cancer. Ann Oncol. 2019;30:1051-60.
[52] Coussy F, El Botty R, Lavigne M, Gu C, Fuhrmann L, Briaux A, et al. Combination of PI3K and MEK inhibitors yields durable remission in PDX models of PIK3CA-mutated metaplastic breast cancers. J Hematol Oncol. 2020;13:13.
[53] Shraim BA, Moursi MO, Benter IF, Habib AM, Akhtar S. The Role of Epidermal Growth Factor Receptor Family of Receptor Tyrosine Kinases in Mediating Diabetes-Induced Cardiovascular Complications. Front Pharmacol. 2021;12:701390.

[54] FDA approves pembrolizumab for high-risk early-stage triple-negative breast cancer. 2021.

[55] Hiss S, Eckstein M, Segschneider P, Mantsoopoulos K, Iro H, Hartmann A, et al. Tumour-Infiltrating Lymphocytes (TILs) and PD-L1 Expression Correlate with Lymph Node Metastasis, High-Grade Transformation and Shorter Metastasis-Free Survival in Patients with Acinic Cell Carcinoma (AcinCC) of the Salivary Glands. Cancers (Basel). 2021;13.

[56] Yu F, Niu L, Wang B, Fan W, Xu J, Chen Q. Two cases of mammary acinic cell carcinomas with microglandular structures mimicking microglandular adenosis. Pathol Int. 2022.

[57] Sen R, Bhutani N, Kamboj J, Dahiya S. Primary acinic cell carcinoma of the breast: A case report with a clinicopathological and immunohistochemical study of a rare breast cancer subtype. Ann Med Surg (Lond). 2018;35:137-40.

[58] Kim M, Kim M, Chung YR, Park SY. Mammary Carcinoma Arising in Microglandular Adenosis: A Report of Five Cases. J Pathol Transl Med. 2017;51:422-7.

[59] Kawai H, Sugimoto R, Iga N, Ikeda H, Yoshida R, Waki N, et al. [A Case of Primary Acinic Cell Carcinoma(ACC)of the Breast]. Gan To Kagaku Ryoho. 2016;43:2019-21.

[60] Sherwell-Cabello S, Maffuz-Aziz A, Rios-Luna NP, Bautista-Pina V, Rodriguez-Cuevas S. Salivary gland-like breast carcinomas: An infrequent disease. Pathol Res Pract. 2016;212:1034-8.

[61] Osako T, Takeuchi K, Horii R, Iwase T, Akiyama F. Secretory carcinoma of the breast and its histopathological mimics: value of markers for differential diagnosis. Histopathology. 2013;63:509-19.

[62] Shingu K, Ito T, Kaneko G, Itoh N. Primary acinic cell carcinoma of the breast: a clinicopathological and immunohistochemical study. Case Rep Oncol Med. 2013;2013:372947.

[63] Choh CT, Komar V, Courtney SP. Primary acinic cell carcinoma of the breast: a rare lesion with good prognosis. Breast J. 2012;18:610-1.

[64] Chang ED, Lee EJ, Lee AW, Kim JS, Kang CS. Primary acinic cell carcinoma of the breast: a case report with an immunohistochemical and ultrastructural studies. J Breast Cancer. 2011;14:160-4.

[65] Matoso A, Easley SE, Gnep DR, Mangray S. Salivary gland acinar-like differentiation of the breast. Histopathology. 2009;54:262-3.

[66] Peintinger F, Leibl S, Reitsamer R, Moinfar F. Primary acinic cell carcinoma of the breast: a case report with long-term follow-up and review of the literature. Histopathology. 2004;45:645-8.

[67] Kahn R, Holtveg H, Nissen F, Holck S. Are acinic cell carcinoma and microglandular carcinoma of the breast related lesions? Histopathology. 2003;42:195-6.

[68] Schmitt FC, Ribeiro CA, Alvarenga S, Lopes JM. Primary acinic cell-like carcinoma of the breast--a variant with good prognosis? Histopathology. 2000;36:286-9.

[69] Shaker N DQ, Wang Y, Li Z. Low-Grade Invasive Triple Negative Breast Carcinoma. J Clin Transl Pathol. 2022.
### Table 1. A summary of clinical and histopathologic characteristics of the acinic cell carcinoma of the breast. The studies were identified through a comprehensive literature search in the major databases (PubMed/MEDLINE, Scopus, and Web of Science Core Collection).

| Sex/Age | Site | Tumor size (mm) | Growth pattern | Radiographic features | Node status | Follow up (months) | Recurrences/Metastases/Outcome |
|---------|------|----------------|----------------|-----------------------|-------------|-------------------|-----------------------------|
| F/59    | R    | 71             | Solid and microglandular | Mammography: An ill-defined solid lesion. | 0/2 | 49 | Peritoneal metastases/DOD |
| F/49    | L uiq R uoq | 35 30 | Solid and microglandular Solid, microglandular and pseudolobular | Mammography: Occult cancer. Mammography: Detected during screening | 0/3 0/3 | | |
| F/42    | L    | 60             | Solid, microlobular and pseudolobular | Ultrasonography: Well-defined, lobulated, solid lesion with characteristics of a fibroadenoma | | 48 | NED |
| F/41    | R uoq | 25             | Acinar and solid | Ultrasonography and mammography: No abnormalities. | 0 | 12 | NED |
| F/52    | L luq | 15             | Cystic and cribriform | | 0/1 | 3 | AW |
| F/38 L 47 60 | L | | | | 0 1a 0 | NED NED NED |
| F/49    | R    | 35             | Solid-trabecular and acinar | Mammography: Lobulated mass with poorly defined margins, without microcalcifications Ultrasonography: A hypoechoic mass with irregular margins. | | 8 | DR |

---

Journal Pre-proof
| Patient | Gender | Age | Histology | Imaging Findings | Follow-up | Outcome |
|---------|--------|-----|-----------|-----------------|-----------|---------|
| /41     | R uoq  | 12  | Acinar-glandular and solid | Mammography: A small oval radiopaque mass | 13        |         |
| /38     |        |     | Microglandular |                      |           | NED     |
| /47     | R luq  | 23  | Microglandular and solid | Mammography: Occult | 1/18      | 72      | DR/Alive with disease |
| /49     | R uoq  | 11  | Microglandular and solid | Ultrasonography: Solid mass associated with innumerable anechoic cysts | 0         | 18      | NED     |
| /36     |        | 50  | Clear cell |                      | 10/17     | 24      | DOD     |
| /34     |        | 19  | Microglandular |                      | 0/8       | 132     | NOD     |
| /42     |        | 11  | Microglandular |                      | 0/3       | 15      | NED     |
| /34     |        | 36  | Microglandular |                      |           | 60      | DR      |
| /48     |        | 20  | Microglandular |                      | 2/22      | 72      | DR      |
| /35     |        | 14  | Microglandular |                      |           |         |         |
| /49     |        | 15  | Microglandular |                      |           |         |         |
| /45     |        | 21  | Microglandular |                      |           |         |         |
| /50     |        | 15  | Microglandular |                      |           |         |         |
| /40     |        | 16  | Microglandular |                      |           |         |         |
| /59     |        | 30  | Microglandular |                      |           |         |         |
| /42     |        | 17  | Microglandular |                      |           |         |         |
| /56     |        | 30  | Microglandular |                      |           |         |         |
| /42     |        | 28  | Microglandular |                      |           |         |         |
| /50     |        | 50  | Microglandular |                      |           |         |         |
| /61     |        | 15  | Microglandular |                      |           |         |         |
| /35     |        | 18  | Microglandular |                      |           |         |         |
| /34     |        | 25  | Microglandular |                      |           |         |         |
| /46     |        | 30  | Microglandular |                      |           |         |         |
| /26     | R lqu  | 16  | Acinic-glandular and solid | | 0/1       | 8       |         |
| /58     | R peri-areolar | 30  | Solid, microglandular and microacinar | Mammography: Thickening with microcalcifications, firm, nodular lesion. | 0/1       | 10      | AW      |
| Case/Year | Age | Laterality | Histology/Imaging Characteristics | Mammography | Ultrasound | MRI | PI | Status |
|-----------|-----|------------|----------------------------------|-------------|------------|-----|----|--------|
| 7/50/13   | F/50 |            | Microglandular, solid and cystic  | 0/30        | 0/23       | 0/4 | 184.8 | NED    |
| 7/37/13   | F/37 |            | Papillary, microglandular, solid  |             |            |     |     | NED    |
| 7/46/13   | F/46 |            |                                  |             |            |     |     | NED    |
| 7/41/13   | L loq| 35         | Solid, trabecular and microglandular | Mammography: Focal asymmetric density of the breast. Ultrasoundography: A heterogeneous hypoechoic mass with ill-defined margins. MRI: High-intensity mass, but no intraductal dissemination. | 0/1        |       | 36   | NED    |
| 7/56/13   | R   | 47         | Solid                             | MRI: Heterogeneous segmental non-mass-like enhancement extending toward the nipple in a triangular configuration. | 0/1        |       | 24   | NED    |
| 7/38/13   | R uoq| 30        | Microglandular                     |             |            |     |     | NED    |
| 7/44/13   | L uoq| 13        | Microglandular                     | MRI: Solid mass with pushing borders. | 0/2        |       | 19   | AW     |
| 7/79/13   | L upper pole | 27 | Solid and microcystic          | Mammography: Dense, inhomogeneous parenchyma; Ultrasoundography: A hypoechoic, irregularly shaped mass with ill-defined borders. | 0/1        |       | 9    | NED    |
| 7/61/13   | R uoq| 14        | Solid and microcystic             |             |            |     |     | NED    |
| 7/39/11   | 55   |            | Acinar/glandular and solid        | Ultrasoundography and mammography: No abnormalities. | 1          |       |      | Unfavorable prognosis |
| 7/40/13   | R uoq| 36        | Microglandular, solid and focally microcystic |             | 1/21       |     | 12   | NED    |
| 7/30/13   | R   | 26         | Microglandular                     |             | 2/33       |     | 34   | Bone metastasis/DOD |
| 7/51/13   | L   | 21         | Microglandular                     |             | 0         |     | 26   | NED    |
| Case | Side | Age | Histology | Imaging Features | Follow-up | Status |
|------|------|-----|-----------|------------------|-----------|--------|
| 7/79 | Luoq | 25 | Solid, microcystic, microglandular and trabecular | Ultrasonography and mammography: Malignant features (no details provided). | 10/15 | 9 AW |
| 5/62 | L    |     |            | Amphophilic cytoplasm with zymogen-like secretory granules |            |        |
| 5/80 | Luoq | 21 | Acinar    | Ultrasonography: A hypoechoic nodule with a smooth surface. Mammography: A well-demarcated mass. No microcalcifications. | 0/1 | 22 AW |
| 5/36 | R    | 35 | Solid and microglandular | | 0/15 | 120 Lung, NED surg. |
| 7/56 | L    | 22 | Solid     | | 0/18 | 28 NED |
| 7/20 | R    | 27 | Papillary/cystic | Mammography and ultrasonography: A solid lesion. | 0 | 6 AW |
| 7/61 | L    | 25 | Papillary/cystic, microcystic and follicular | Mammography and ultrasonography: An irregular-shaped mass with microcalcifications. | 0 | 24 NED |
| 7/59 | R    | 10 | Microfollicular | | 0 | 94 NED |
| 7/49 | R    | 20 | Microglandular | | 2/11 | 36 Liver |
| 7/42 | Luoq | 30 | Solid     | | 1/18 | 60 AW |
| 7/35 | Luoq | 40 | Microglandular | | 2/20 | 12 AW |
| 7/63 | L    | 50 | Microglandular | | 0/20 | 48 AW |
| 7/55 | L    | 20 | Microglandular | | 0/20 | 12 DR |
| 7/64 | Liuq | 33 | Microglandular | | 0/8 | 12 AW |
| 7/80 | Luoq | 20 | Microglandular | | 0/8 | 12 AW |
| 7/79 | Liuq | 45 | Solid     | | 0/23 | 21 NED |
| M/23 | L    | 48 | Solid     | Ultrasonography: A clear marginal cystic mass composed of hypoechoic intracystic fluid and a | | 34 NED |
|    |    |    | hyperechoic intracystic tumor |
|----|----|----|-----------------------------|
| F/42 | R uoq | 30 | Solid | Mammography: A mass with well-defined margins with scattered granular calcifications. | 1/18 | 60 | AW |
F – female; M – male; AW – Alive and well; DOD – Died of disease, DR – disease recurrence, ioq – inferior outer quadrant; L – left; loq – lower outer quadrant; lqu – lower quadrant union; R – right; NED – no evidence of disease, uiq – upper internal quadrant; uoq – upper outer quadrant
Table 2. Overview of the reported treatment modalities used for the treatment of acinic cell carcinoma of the breast.

| Author (year)          | Surgery                        | Adjuvant therapy |
|------------------------|--------------------------------|------------------|
| 1 Sarsiat et al. (2022)[14] | BCS + SLND                     | Neo-CT           |
| 2 Yu et al. 3 (2022)[56]    | MRM + SLND BCS + SLND         | -                |
| 4 Waever et al. (2021)[19]  | Mastectomy + SLND             | Neo-CT           |
| 5 Sen et al. (2018)[57]     | MRM + ALND                     | -                |
| 6 Li et al. (2017)[30]      | Mastectomy                     | -                |
| 7 Kim et al. 8 (2017)[58]   | BCS BCS                        | CT + RT CT + RT  |
| 10 Kawai et al. (2016)[59]  | MRM + SLND                     | CT               |
| 11 Xu et al. (2016)[20]     | BCS                            | Neo-CT           |
| 12 Sherwell-Cabello et al. (2016) [60] | na                             | na               |
| 13 Conlon et al. 14 (2016)[7] | B/L mastectomy + ALND BCS     | CT Neo-CT        |
| 15 Guerini-16 Rocco et 17 al. (2015)[23] | na                            | na               |
| 23 Piscuoglio 24 et al. (2015)[11] | na                            | na               |
| 25 Zhong et al. 26 (2014)[8]  | BCS BCS                        | CT + RT CT + RT  |
| No.  | Study Authors               | Treatment 1          | Treatment 2          |
|------|-----------------------------|----------------------|----------------------|
| 27   |                             | Mastectomy           | CT                   |
| 28   |                             | BCS                  | CT + RT              |
| 29   |                             | Mastectomy           | CT                   |
| 30   |                             | Mastectomy           | CT                   |
| 31   |                             | Mastectomy           | CT                   |
| 32   |                             | Mastectomy           | CT                   |
| 33   |                             | BCS                  | CT + RT              |
| 34   |                             | Mastectomy           | CT                   |
| 35   |                             | Mastectomy           | CT                   |
| 36   | Limite et al. (2014)[24]    | BCS + SLND           | -                    |
| 37   | Falleti et al. (2013)[32]   | BCS + SLND           | -                    |
| 38   | Osako et al. (2013)[61]     | MRM + ALND           | -                    |
| 39   |                             | BCS + ALND           | -                    |
| 40   |                             | MRM + SLND           | -                    |
| 41   | Shingu et al. (2013)[62]    | BCS + SLND           | CT + RT              |
| 42   | Winkler et al. (2013)[15]   | MRM + SLND           | Neo-CT+ HT           |
| 43   | Zhao et al. (2014)[12]      | MRM + ALND           | CT                   |
| 44   | Ripamonti et al. (2013)[16] | MRM + SLND           | HT                   |
| 45   | Choh et al. (2012)[63]      | BCS + SLND           | RT                   |
| 46   | Sakuma et al. (2013)[31]    | BCS + ALND           | -                    |
| 47   | Chang et al. (2011)[64]     | BCS + ALND           | -                    |
| 48   | Huo et al. (2011)[17]       | MRM + ALND           | Neo-CT + RT + HT     |
| 49   |                             | BCS + ALND           | CT + RT              |
| 50   |                             | BCS + SLND           | -                    |
| 51   | Stolnicu et al. (2010)[35]  | MRM + ALND           | -                    |
| 52   | Matoso et al. (2009)[65]    | na                   | na                   |
| Reference | Treatment 1 | Treatment 2 | Additional Treatment |
|-----------|-------------|-------------|----------------------|
| Tanahashi et al. (2007) [33] | MRM + SLND | - | |
| Peintinger et al. (2004) [66] | BCS + ALND | CT + RT | |
| Kahn et al. (2003) [67] | MRM + ALND | - | |
| Hirokawa et al. (2002) [34] | MRM + ALND | - | |
| | MRM + ALND | - | |
| | MRM + ALND | - | |
| | MRM + ALND | - | |
| Coyne et al. (2002) [21] | MRM + ALND | Neo-CT + CT | |
| Damiani et al. (2000) [18] | MRM | CT | |
| | MRM + ALND | Neo-CT | |
| | BCS | - | |
| | BCS | - | |
| | BCS + ALND | - | |
| | BCS | HT | |
| Schmitt et al. (2000) [68] | MRM + ALND | RT | |
| Shimao et al. (1998) [10] | BCS + ALND | - | |
| Roncaroli et al. (1996) [6] | MRM + ALND | CT | |
ALND – Axillary lymph node dissection; BCS – Breast-conserving surgery; B/L – Bilateral; CT – Chemotherapy (adjuvant); HT – Hormone therapy; MRM – Modified radical mastectomy; Neo-CT – Neoadjuvant chemotherapy; RT – Radiation therapy; na – Not available; SLND – Sentinel lymph node dissection
Records identified through database search:
- PubMed (n=254)
- Scopus (n=132)
- Web of Science (n=186)
- Total (n=572)

Records removed before screening (514):
- Duplicates records and reviews removed (n=382)
- Records removed because title and/or abstract did not match the topic of the review (n=132)

Records screened (n=58)

Records excluded:
- Records with only title or abstract available (n=19)
- Records written in a language other than English (n=1)

Full articles assessed for eligibility (n=38)

Studies included in the review (n=38)
**Highlights**

- Acinic cell carcinoma of the breast is a very rare subtype of breast cancer.
- It is morphologically similar to acinic cell carcinomas of salivary glands and pancreas and has a triple-negative phenotype.
- Its molecular genomic features are more similar to TNBC NST than to its salivary gland counterpart.
- The clinical course of the mammary acinic cell carcinoma appears to be less aggressive than the usual TNBC.